Form 4: ADC Therapeutics Director Victor Sandor Awarded 40,000 Restricted Stock Units

ADC Therapeutics SA Director Victor Sandor has been granted 40,000 restricted stock units as part of his annual compensation, aligning his interests with shareholders.

Summary

• Victor Sandor, a Director of ADC Therapeutics SA (ADCT), acquired 40,000 Common Shares in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• The RSUs were granted at a price of $0, indicating they are part of an equity compensation plan.
• This grant represents the annual award of RSUs under the Issuer's 2019 Equity Incentive Plan for his service as a Director.
• The RSUs are scheduled to vest one year from the grant date, subject to Mr. Sandor's continued service to the Issuer.
• Each RSU provides a contingent right to receive one share of ADC Therapeutics' common stock.
• Following this transaction, Victor Sandor beneficially owns a total of 120,886 Common Shares directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the RSU grant aligns the director's interests with shareholders and is a standard, expected form of compensation, indicating stability in governance and compensation practices. It does not, however, signal a major operational or financial breakthrough.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Victor Sandor aligns his financial interests with those of the company's shareholders, as the value of his compensation is tied to the future performance of ADCT's stock.
• This is a standard annual equity incentive, indicating a consistent approach to director compensation and retention.

Negatives

• While not an immediate negative, the vesting of these RSUs in the future will lead to an increase in the outstanding share count, which could result in minor dilution for existing shareholders if not already factored into the company's share count projections.

Future Outlook

The vesting of the 40,000 Restricted Stock Units is contingent upon Director Victor Sandor's continued service to ADC Therapeutics for one year from the grant date.

Industry Context

The granting of Restricted Stock Units (RSUs) is a common practice in the biotechnology and pharmaceutical industries for compensating directors and executives, aiming to incentivize long-term commitment and align management interests with shareholder value creation. This practice is consistent with industry standards for attracting and retaining experienced board members.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely adopted practice across the biotechnology and pharmaceutical sectors, similar to companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity-based incentives to align leadership with long-term company performance.
• The vesting schedule of one year is a common period for annual RSU grants to directors, ensuring continued engagement and oversight.

Related Party Transactions

• The grant of 40,000 Restricted Stock Units to Director Victor Sandor constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, it also represents a future dilutive event when the shares vest, though this is typically accounted for in valuation models.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The 40,000 RSUs granted to Victor Sandor are expected to vest on June 3, 2026, assuming his continued service as a Director.

Key Dates

Recommendation

Keywords

ADC Therapeutics, ADCT, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Insider Ownership, SEC Form 4, Biotechnology, Pharmaceuticals